Wegovy pill vs. Foundayo: the two GLP-1 weight-loss tablets compared

Both tablets activate the GLP-1 receptor once a day, but they are built very differently. Semaglutide is a peptide that stomach enzymes would normally destroy, so the Wegovy tablet carries an absorption enhancer, salcaprozate sodium (SNAC), and only works if it reaches an empty stomach: one tablet in the morning with up to four ounces of plain water, then at least 30 minutes before food, other drinks or other pills. Orforglipron is a small non-peptide molecule that survives digestion on its own, so the Foundayo label allows it with or without food at any time of day. Titration differs too. The Wegovy tablet moves 1.5 mg, 4 mg, 9 mg and then 25 mg at 30-day steps. Foundayo starts at 0.8 mg, moves to 2.5 mg and 5.5 mg after at least 30 days each, and can then rise to 9 mg, 14.5 mg or a 17.2 mg maximum. Only the Wegovy tablet also carries a cardiovascular risk-reduction indication.

No trial has tested the Wegovy pill against Foundayo. Each label reports its own placebo-controlled study, and both use intention-to-treat figures. In Study 7 (OASIS 4), 307 adults without diabetes took oral semaglutide 25 mg or placebo for 64 weeks; weight fell 13.6% against 2.4%, and 27.9% of the semaglutide group lost at least 20% of body weight, against 3.1% on placebo. In the Foundayo label's Trial 1 (ATTAIN-1), 3,127 adults without diabetes were followed for 72 weeks; weight fell 7.4% on 5.5 mg, 8.3% on 9 mg and 11.1% on 17.2 mg, against 2.1% on placebo. In adults with type 2 diabetes (Trial 2), the same doses reached 5.1%, 7.0% and 9.6%. There is one head-to-head trial, ACHIEVE-3 (The Lancet, 2026), but it compared orforglipron with Rybelsus-strength oral semaglutide, 7 mg and 14 mg, in 1,698 adults with type 2 diabetes. Orforglipron lowered HbA1c by 1.71 to 1.91 points against 1.23 to 1.47 for semaglutide at 52 weeks. It says nothing about oral semaglutide at the 25 mg Wegovy dose.

Both tablets share the GLP-1 pattern of nausea, vomiting, diarrhea and constipation, worst while doses are rising. The Wegovy label says the tablet's common reactions matched Wegovy 2.4 mg injection in type and frequency, where nausea reached 44%, diarrhea 30% and vomiting 24%; 6.9% on the 25 mg tablet stopped for adverse reactions against 5.9% on placebo, and 5% reported dysesthesia against none on placebo. Foundayo's label pools its two weight trials: nausea 26-35% by dose against 10% on placebo, vomiting 13-24%, constipation 20-27% and diarrhea 21-25%, with 8% stopping for adverse reactions against 3%. Foundayo also raised resting heart rate by 4 to 5 beats per minute, hair loss was reported in 7% of women, and its dose is capped at 9 mg with strong CYP3A4 inhibitors. Both carry the thyroid C-cell tumor boxed warning and the MTC and MEN 2 contraindication.

The Wegovy pill fits someone who wants the larger label weight-loss figure from a tablet, already has a steady morning routine, and values the cardiovascular indication. Its weak point is the ritual: an empty stomach, four ounces of water at most, and a 30-minute wait before coffee, breakfast or other medicines. Anyone with other medicines fixed to early morning should plan around that 30-minute rule with a prescriber. Foundayo fits someone for whom that ritual would fail, such as shift workers, people with irregular mornings, or anyone who wants to take a pill with lunch. The trade is a smaller average effect in its own trial, a heart-rate rise, and interaction limits with strong CYP3A4 inhibitors. Cost can separate them at the start: NovoCare lists the Wegovy tablet at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg (NovoCare Wegovy price guide, April 2026 edition, checked 28 Sep 2026), and Temi lists Foundayo at $149 a month for 0.8 mg (usetemi.com/medications/foundayo, checked 28 Sep 2026). Neither suits someone with a personal or family history of medullary thyroid carcinoma or MEN 2, or someone whose goals call for an injectable's larger effect.